MCID: CHG001
MIFTS: 72

Chagas Disease

Categories: Rare diseases, Infectious diseases, Neuronal diseases

Aliases & Classifications for Chagas Disease

MalaCards integrated aliases for Chagas Disease:

Name: Chagas Disease 12 72 49 55 51 40 3 14 69
American Trypanosomiasis 12 72 49 55 3
Chagas' Disease with Digestive System Involvement 12
Chagas' Disease with Nervous System Involvement 12
Chagas' Disease with Other Organ Involvement 12
South American Trypanosomiasis 49
New World Trypanosomiasis 49
Chagas' Disease 12

Characteristics:

Orphanet epidemiological data:

55
american trypanosomiasis
Inheritance: Not applicable; Prevalence: 6-9/10000 (United States); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 55  
Rare infectious diseases


Summaries for Chagas Disease

NIH Rare Diseases : 49 Chagas disease is caused by the parasite, Trypanosoma cruzi. The triatomine bug, which can carry the parasite, most often bites a person's face and therefore is more commonly known as the "kissing bug". When a triatomine bug infected with Trypanosoma cruzi bites, it can leave behind infected waste which can be spread into the person's eyes, nose, or a wound. Chagas disease can also spread through contaminated food, a blood transfusion, a donated organ, or from mother to baby during pregnancy. Symptoms may include fever, flu-like symptoms, a rash, or swollen eyelid. Early symptoms usually go away without treatment, but can last a few weeks or months. However, if not treated in the early phase, the parasite can become active again years later. In fact, 20-30% of infected people will later develop serious problems affecting their heart, intestines, or espophagus. This risk is greater for those with a weakened immune system. Chagas disease is common in Latin America, but not in the United States. On August 30, 2017, the FDA approved benznidazole to treat Chagas disease in children between the ages of 2 to 12 years old. Nifurtimox may also used to treat Chagas disease. Although not FDA approved, nifurtimox can be obtained for the treatment of Chagas disease in the United States through special CDC studies. Similarly, benznidazole is also available through special CDC studies for those with Chagas disease whose treatment is deemed necessary by their doctor but whose age falls outside FDA approval. Last updated: 9/18/2017

MalaCards based summary : Chagas Disease, also known as american trypanosomiasis, is related to idiopathic achalasia and sleeping sickness, and has symptoms including pallor, skin rash and cardiomyopathy. An important gene associated with Chagas Disease is IL10 (Interleukin 10), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Carvedilol and Enalapril have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and eye, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Disease Ontology : 12 A trypanosomiasis that is a tropical parasitic disease caused by the flagellate protozoan Trypanosoma cruzi, which is transmitted to humans and other mammals by an insect vector, the blood-sucking assassin bugs of the subfamily Triatominae (family Reduviidae), most commonly species belonging to the Triatoma, Rhodnius, and Panstrongylus genera. The symptoms include fever, fatigue, body aches, headache, rash, loss of appetite, diarrhea, vomiting, swelling of the eyelids and myocarditis.

MedlinePlus : 40 Chagas disease is caused by a parasite. It is common in Latin America but not in the United States. Infected blood-sucking bugs, sometimes called kissing bugs, spread it. When the bug bites you, usually on your face, it leaves behind infected waste. You can get the infection if you rub it in your eyes or nose, the bite wound or a cut. The disease can also spread through contaminated food, a blood transfusion, a donated organ or from mother to baby during pregnancy. If you notice symptoms, they might include Fever Flu-like symptoms A rash A swollen eyelid These early symptoms usually go away. However, if you don't treat the infection, it stays in your body. Later, it can cause serious intestinal and heart problems. A physical exam and blood tests can diagnose it. You may also need tests to see whether the disease has affected your intestines and heart. Medicines can kill the parasite, especially early on. You can also treat related problems. For example, a pacemaker helps with certain heart complications. There are no vaccines or medicines to prevent Chagas disease. If you travel to areas where it occurs, you are at higher risk if you sleep outdoors or in poor housing conditions. It is important to use insecticides to prevent bites, and practice food safety. Centers for Disease Control and Prevention

CDC : 3 Chagas disease is named after the Brazilian physician Carlos Chagas, who discovered the disease in 1909. It is caused by the parasite Trypanosoma cruzi, which is transmitted to animals and people by insect vectors and is found only in the Americas (mainly, in rural areas of Latin America where poverty is widespread). Chagas disease (T. cruzi infection) is also referred to as American trypanosomiasis.

Wikipedia : 72 Chagas disease, also known as American trypanosomiasis, is a tropical parasitic disease caused by the... more...

Related Diseases for Chagas Disease

Diseases related to Chagas Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 390)
# Related Disease Score Top Affiliating Genes
1 idiopathic achalasia 31.0 IL10 NOS2 TNF
2 sleeping sickness 30.8 IL10 IL6 NOS2
3 trypanosomiasis 30.8 CALR CCL2 CCL3 CXCL8 IFNG IL10
4 esophagitis 30.6 CXCL8 IL1B IL6 TGFB1
5 mucocutaneous leishmaniasis 30.1 CCR5 IL10 TNF
6 salmonellosis 30.1 IFNG IL1B TLR4
7 leprosy 3 30.0 IFNG IL10 IL2 TLR2 TNF
8 cysticercosis 29.9 IL12B IL1B IL6 TLR4
9 leishmaniasis 29.8 IFNG IL10 IL12B IL1B NOS2 TGFB1
10 schistosomiasis 29.8 CCL3 IFNG IL10 IL2 TNF
11 systolic heart failure 29.8 ACE IL6 NPPB
12 autoimmune disease 29.6 IFNG IL10 IL1B IL2 IL6 TNF
13 myocarditis 29.6 IL6 NOS2 NPPB TNF
14 filariasis 29.5 IFNG IL10 IL2 IL6 TLR2 TLR4
15 visceral leishmaniasis 29.3 CXCL8 IFNG IL10 IL1B IL2 NOS2
16 hypertrophic cardiomyopathy 29.0 ACE IL6 NPPB TGFB1 TNF
17 arteries, anomalies of 28.8 ACE CCL2 IL1B IL6 NPPB TNF
18 acquired immunodeficiency syndrome 28.8 CCL3 CCR5 IFNG IL10 IL1B IL2
19 dilated cardiomyopathy 28.5 ACE CALR IL10 IL1B IL6 NPPB
20 systemic lupus erythematosus 27.9 CALR CCL2 CCR5 IFNG IL10 IL1B
21 malaria 27.8 CCL2 CCL3 CXCL8 IFNG IL10 IL12B
22 punctate inner choroidopathy 10.7 IL10 TNF
23 oral tuberculosis 10.6 IL2 TNF
24 tropical endomyocardial fibrosis 10.6 IL10 TNF
25 poliomyelitis 10.6 IFNG IL10 TNF
26 autoimmune myocarditis 10.6 IFNG IL2 TNF
27 polyposis, gastric 10.6 IL1B TNF
28 trench fever 10.6 TLR2 TLR4 TNF
29 spotted fever 10.6 IFNG IL10 TNF
30 staphylococcal toxic shock syndrome 10.6 IFNG IL1B TNF
31 juvenile myasthenia gravis 10.6 IL10 TGFB1
32 penicilliosis 10.6 TLR2 TLR4 TNF
33 scorpion envenomation 10.5 IL6 TNF
34 alveolar echinococcosis 10.5 TLR2 TLR4 TNF
35 tuberculoid leprosy 10.5 IFNG IL10 TGFB1
36 myositis fibrosa 10.5 IFNG TLR2 TLR4
37 posterior uveitis 10.5 IFNG IL2 TNF
38 fascioliasis 10.5 IFNG IL10 IL1B
39 prosthetic joint infection 10.5 IL1B TLR2 TLR4
40 listeriosis 10.5 IL10 IL6 TNF
41 erythema multiforme 10.5 IFNG IL2 TNF
42 post-transplant lymphoproliferative disease 10.5 IL10 IL6 TNF
43 hyperlucent lung 10.5 IFNG IL10
44 tungiasis 10.5 CXCL8 IL10 TNF
45 campylobacteriosis 10.5 IFNG IL1B TLR4
46 multicentric castleman disease 10.5 IFNG IL10 IL6
47 suppurative otitis media 10.5 IL1B TLR2 TLR4
48 trichuriasis 10.5 CXCL8 IL10 TNF
49 anterior uveitis 10.5 IL6 TLR4 TNF
50 radiculopathy 10.5 CCL2 IL10 IL6

Graphical network of the top 20 diseases related to Chagas Disease:



Diseases related to Chagas Disease

Symptoms & Phenotypes for Chagas Disease

Human phenotypes related to Chagas Disease:

55 31 (show all 27)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 pallor 55 31 frequent (33%) Frequent (79-30%) HP:0000980
2 skin rash 55 31 frequent (33%) Frequent (79-30%) HP:0000988
3 cardiomyopathy 55 31 frequent (33%) Frequent (79-30%) HP:0001638
4 splenomegaly 55 31 frequent (33%) Frequent (79-30%) HP:0001744
5 thromboembolism 55 31 frequent (33%) Frequent (79-30%) HP:0001907
6 fever 55 31 frequent (33%) Frequent (79-30%) HP:0001945
7 diarrhea 55 31 frequent (33%) Frequent (79-30%) HP:0002014
8 abdominal pain 55 31 frequent (33%) Frequent (79-30%) HP:0002027
9 dyspnea 55 31 frequent (33%) Frequent (79-30%) HP:0002094
10 hepatomegaly 55 31 frequent (33%) Frequent (79-30%) HP:0002240
11 headache 55 31 frequent (33%) Frequent (79-30%) HP:0002315
12 lymphadenopathy 55 31 frequent (33%) Frequent (79-30%) HP:0002716
13 myalgia 55 31 frequent (33%) Frequent (79-30%) HP:0003326
14 localized skin lesion 55 31 frequent (33%) Frequent (79-30%) HP:0011355
15 arrhythmia 55 31 frequent (33%) Frequent (79-30%) HP:0011675
16 cough 55 31 frequent (33%) Frequent (79-30%) HP:0012735
17 myocarditis 55 31 frequent (33%) Frequent (79-30%) HP:0012819
18 autoimmune antibody positivity 55 31 frequent (33%) Frequent (79-30%) HP:0030057
19 periorbital edema 55 31 frequent (33%) Frequent (79-30%) HP:0100539
20 congestive heart failure 55 31 occasional (7.5%) Occasional (29-5%) HP:0001635
21 aganglionic megacolon 55 31 occasional (7.5%) Occasional (29-5%) HP:0002251
22 achalasia 55 31 occasional (7.5%) Occasional (29-5%) HP:0002571
23 abnormal large intestine physiology 55 31 occasional (7.5%) Occasional (29-5%) HP:0012700
24 encephalitis 55 31 very rare (1%) Very rare (<4-1%) HP:0002383
25 peripheral neuropathy 55 31 very rare (1%) Very rare (<4-1%) HP:0009830
26 edema 55 Frequent (79-30%)
27 abnormality of the nervous system 55 Very rare (<4-1%)

UMLS symptoms related to Chagas Disease:


pruritus, fever

GenomeRNAi Phenotypes related to Chagas Disease according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.83 ACE CXCL8 IL10 IL1B IL2 NOS2
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.83 TNF ACE CXCL8 IL10 IL1B IL2

MGI Mouse Phenotypes related to Chagas Disease:

43 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.43 ACE CALR CCR5 CYP51A1 IFNG IL10
2 homeostasis/metabolism MP:0005376 10.39 TNF ACE CALR CCR5 CYP51A1 IFNG
3 growth/size/body region MP:0005378 10.38 TNF ACE CALR CYP51A1 IFNG IL10
4 immune system MP:0005387 10.37 ACE CCL2 CCR5 CYP51A1 IFNG IL10
5 digestive/alimentary MP:0005381 10.34 IFNG IL10 IL12B IL2 IL6 NOS2
6 hematopoietic system MP:0005397 10.34 TLR4 TNF ACE CCR5 IFNG IL10
7 behavior/neurological MP:0005386 10.33 ACE CCR5 IFNG IL10 IL2 IL6
8 cellular MP:0005384 10.32 CALR CCR5 IFNG IL10 IL2 IL6
9 mortality/aging MP:0010768 10.31 ACE CALR CCR5 CYP51A1 IFNG IL10
10 endocrine/exocrine gland MP:0005379 10.2 NOS2 TGFB1 TLR2 TNF ACE IFNG
11 liver/biliary system MP:0005370 10.2 IL6 NOS2 TGFB1 TLR2 TLR4 TNF
12 neoplasm MP:0002006 10.18 ACE CCR5 IFNG IL10 IL12B IL1B
13 craniofacial MP:0005382 10.17 IL10 IL12B IL1B NOS2 TGFB1 TNF
14 adipose tissue MP:0005375 10.14 ACE IL6 NOS2 TGFB1 TLR2 TLR4
15 muscle MP:0005369 10.14 TGFB1 TLR2 TLR4 TNF CALR CCR5
16 integument MP:0010771 10.13 IL6 NOS2 TGFB1 TLR2 TLR4 TNF
17 nervous system MP:0003631 10.06 IL6 NOS2 TGFB1 TLR2 TLR4 TNF
18 reproductive system MP:0005389 9.96 ACE CCR5 IFNG IL10 IL2 IL6
19 respiratory system MP:0005388 9.85 IFNG IL10 IL12B IL2 IL6 NOS2
20 skeleton MP:0005390 9.7 CYP51A1 IFNG IL10 IL12B IL1B IL6
21 vision/eye MP:0005391 9.28 CCR5 IFNG IL10 IL2 IL6 NOS2

Drugs & Therapeutics for Chagas Disease

Drugs for Chagas Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 72)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
2
Enalapril Approved, Vet_approved Phase 4 75847-73-3 40466924 5362032
3
Enalaprilat Approved Phase 4 76420-72-9 6917719
4
Warfarin Approved Phase 4 81-81-2 54678486 6691
5
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
6 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
7 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Phase 1
8 Antiprotozoal Agents Phase 4,Phase 3,Phase 2,Phase 1
9 Benzonidazole Phase 4,Phase 3,Phase 2
10 Immunosuppressive Agents Phase 4,Phase 3,Phase 2
11 Adrenergic Agents Phase 4,Phase 3
12 Adrenergic alpha-1 Receptor Antagonists Phase 4
13 Adrenergic alpha-Antagonists Phase 4
14 Adrenergic Antagonists Phase 4,Phase 3
15 Adrenergic beta-Antagonists Phase 4,Phase 3
16 Angiotensin-Converting Enzyme Inhibitors Phase 4
17 Antihypertensive Agents Phase 4,Phase 3
18 HIV Protease Inhibitors Phase 4
19 Natriuretic Peptide, Brain Phase 4
20 Neurotransmitter Agents Phase 4,Phase 3
21
protease inhibitors Phase 4
22 Vasodilator Agents Phase 4,Phase 3
23 Anticoagulants Phase 4
24 Peripheral Nervous System Agents Phase 4,Phase 3
25 Analgesics Phase 4
26 Analgesics, Non-Narcotic Phase 4
27 Anti-Inflammatory Agents Phase 4
28 Anti-Inflammatory Agents, Non-Steroidal Phase 4
29 Antipyretics Phase 4
30 Antirheumatic Agents Phase 4
31 Cyclooxygenase Inhibitors Phase 4
32 Fibrinolytic Agents Phase 4
33 Platelet Aggregation Inhibitors Phase 4
34
Coumarin Experimental, Nutraceutical Phase 4 91-64-5 323
35
Bisoprolol Approved Phase 3 66722-44-9 2405
36
Selenium Approved, Investigational, Vet_approved Phase 3 7782-49-2
37
Amiodarone Approved, Investigational Phase 3 1951-25-3 2157
38
Coal tar Approved Phase 3 8007-45-2
39
Ornithine Approved, Nutraceutical Phase 3 70-26-8, 3184-13-2 6262
40 Nifurtimox Investigational Phase 2, Phase 3, Phase 1 23256-30-6
41 Melarsoprol Investigational Phase 3 494-79-1
42 Adrenergic beta-1 Receptor Antagonists Phase 3
43 Autonomic Agents Phase 3
44 Sympatholytics Phase 3
45 Cytochrome P-450 Enzyme Inhibitors Phase 3,Phase 2
46 Antioxidants Phase 3
47 Micronutrients Phase 3
48 Protective Agents Phase 3
49 Sodium Selenite Phase 3
50 Trace Elements Phase 3

Interventional clinical trials:

(show top 50) (show all 61)

# Name Status NCT ID Phase Drugs
1 Optimization of PCR Technique to Assess Parasitological Response for Patients With Chronic Chagas Disease Unknown status NCT01678599 Phase 4 Benznidazole
2 Population Pharmacokinetics Study of Benznidazole in Children With Chagas'Disease Unknown status NCT01549236 Phase 4 Benznidazole 12,5mg or 100mg
3 Population Pharmacokinetics in Benznidazole-treated Adults With Chronic With Chagas Disease Completed NCT01755403 Phase 4 Benznidazole
4 Exercise Training in Chagas Cardiomyopathy Completed NCT01006473 Phase 4
5 A Randomized Trial of Carvedilol in Chronic Chagas Cardiomyopathy Completed NCT01557140 Phase 4 RASi plus carvedilol
6 Outcomes of an Anticoagulation Clinic in an University Hospital Completed NCT01006486 Phase 4
7 Clinical Assessment, Neuroimaging and Immunomarkers in Chagas Disease Study (CLINICS) Recruiting NCT01650792 Phase 4 Aspirin
8 Reveal Chagas: Clinical Evidence of the Implantable Cardiac Monitor in Patients With Chagas Disease Terminated NCT01539161 Phase 4
9 BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas' Disease Unknown status NCT00123916 Phase 3 Benznidazole;Placebo
10 Etiologic Treatment With Benznidazole in Adult Patients With Chronic Chagas Disease. A Randomized Clinical Trial Completed NCT02386358 Phase 3 Benznidazole;Placebo
11 Physical Exercise Program in Chronic Chagas Heart Disease Completed NCT02517632 Phase 3
12 Cardiac Rehabilitation in Chagas Heart Failure Completed NCT02516293 Phase 2, Phase 3
13 Chagas Cardiomyopathy Bisoprolol Intervention Study: Charity Completed NCT00323973 Phase 3 Bisoprolol
14 Selenium Treatment and Chagasic Cardiopathy (STCC) Recruiting NCT00875173 Phase 3 Selenium;Placebo (for Selenium)
15 CHICAMOCHA 3 - Equivalence of Usual Interventions for Trypanosomiasis (EQUITY) Recruiting NCT02369978 Phase 2, Phase 3 Nifurtimox;Benznidazole;Placebo
16 A Trial Testing Amiodarone in Chagas Cardiomiopathy Recruiting NCT03193749 Phase 3 Amiodarone Hydrochloride;Placebo Oral Tablet
17 Prospective Study of a Pediatric Nifurtimox Formulation for Chagas' Disease Active, not recruiting NCT02625974 Phase 3 Nifurtimox (BAYA2502);Nifurtimox (BAYA2502) followed by Placebo
18 Randomized Clinical Trial of Three Drug Combinations for Late-Stage Gambiense Human African Trypanosomiasis Terminated NCT00330148 Phase 3 melarsoprol 1.8 mg/kg/d, 10d + nifurtimox 15/20 mg/kg/d, 10d;melarsoprol 1.8 mg/kg/d, 10d + eflornithine 400 mg/kg/d, 7d;nifurtimox 15/20 mg/kg/d 10d + eflornithine 400 mg/kg/d 7d
19 Cell Therapy in Chagas Cardiomyopathy Terminated NCT00349271 Phase 3 Filgrastime (G-CSF);Standart therapy
20 Proof-of-Concept Study of E1224 to Treat Adult Patients With Chagas Disease Unknown status NCT01489228 Phase 2 E1224;Benznidazole;Placebo
21 Study to Evaluate Fexinidazole Dosing Regimens for the Treatment of Adult Patients With Chagas Disease Unknown status NCT02498782 Phase 2 Fexinidazole;Placebo
22 A Study of the Use of Oral Posaconazole (POS) in the Treatment of Asymptomatic Chronic Chagas Disease (P05267) Completed NCT01377480 Phase 2 Posaconazole;Placebo for posaconazole;Benznidazole
23 Clinical Trial For The Treatment Of Chronic Chagas Disease With Posaconazole And Benznidazole Completed NCT01162967 Phase 2 Benznidazole;Posaconazole
24 Safety and Efficacy Study of Stem Cell Transplantation to Treat Dilated Cardiomyopathy Completed NCT00629018 Phase 2 Bone Marrow Stimulation
25 Evaluation of Different Benznidazole Regimens for the Treatment of Chronic Chagas Disease. Recruiting NCT03191162 Phase 2 Benznidazole
26 BENDITA BEnznidazole New Doses Improved Treatment and Associations Active, not recruiting NCT03378661 Phase 2 Benznidazole;E1224;E1224 Placebo;Benznidazole Placebo
27 Evaluation of G-CSF (Colony Stimulating Factor) in Patients With Chronic Chagas Cardiomyopathy Enrolling by invitation NCT02154269 Phase 2 Treatment with G-CSF (Granulocyte colony stimulating factor);Placebo saline
28 Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas' Patients Completed NCT02606864 Phase 1 Nifurtimox (BAYa2502)
29 Study to Assess Bioequivalence of 30 and 120 mg Nifurtimox Tablets in Chronic Chagas' Patients Completed NCT01927224 Phase 1 Nifurtimox (BAYa2502) (4 x 30 mg tablet);Nifurtimox (BAYa2502) (slurry of 4 x 30 mg tablets in tap water);Nifurtimox (BAYa2502) (120 mg tablet)
30 Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas' Patients - Dietary Habits Study Not yet recruiting NCT03334838 Phase 1 Nifurtimox (Lampit, BAYA2502)
31 Study Will Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro Dissolution Characteristics, and to Evaluate the Relative Bioavailability of Nifurtimox 30 mg and 120 mg Not yet recruiting NCT03350295 Phase 1 Nifurtimox (Lampit, BAYA2502)
32 Prevalence of Chagas Disease in Immigrant Patients With Conduction Abnormalities on Electrocardiogram Unknown status NCT00453700
33 Renal Denervation in Patients With Heart Failure Secondary to Chagas Disease Unknown status NCT02099903
34 Exercise Training in Patients With Chagasic Heart Disease Without Ventricular Dysfunction Unknown status NCT02295215
35 Impact of the Pharmaceutical Care on the Quality of Life in Patients With Chagas Heart Disease Unknown status NCT01566617
36 Feasibility of Contact Force Catheter Mapping and Ablation in Epicardial and Endocardial Ventricular Tachycardias Unknown status NCT01847378
37 Assessment of Speckle Tracking Strain Predictive Value for Myocardial Fibrosis in Chagas Disease Completed NCT02327052
38 MicroRNAs as Biomarkers in Patients With Chagas Disease Completed NCT01842880
39 Galectin-3 as a Biomarker in Patients With Chagas Disease Completed NCT01842854
40 Syndecan-4 as a Biomarker in Patients With Chagas Disease Completed NCT01842867
41 New Tools for the Diagnosis, Prognosis and Treatment Follow-up in Chagas Disease Completed NCT01755377 Benznidazole
42 Study Of Nifurtimox Transfer Into Breastmilk In Lactating Women With Chagas Disease Completed NCT01744405
43 Study of Benznidazole Transfer Into Breastmilk in Lactating Women With Chagas Disease Completed NCT01547533
44 Population Pharmacokinetics of Benznidazole in Children With Chagas Disease Completed NCT00699387 Benznidazole
45 Chagas Disease Diagnostic - Inconclusive Serology Completed NCT00511589
46 Determination of Genetic Polymorphisms in Chronic Chagas Cardiomyopathy Completed NCT02346123
47 Congenital Transmission of Lineages I and II of Trypanosoma Cruzi Completed NCT01787968
48 Longitudinal Study of Patients With Chronic Chagas Cardiomyopathy in Brazil (SaMi_Trop Project) Completed NCT02646943
49 Chagas Disease as an Undiagnosed Type of Cardiomyopathy in the United States Completed NCT00005455
50 Abbott ESA Chagas Assay Post-Market Study Completed NCT01662362

Search NIH Clinical Center for Chagas Disease

Genetic Tests for Chagas Disease

Anatomical Context for Chagas Disease

MalaCards organs/tissues related to Chagas Disease:

38
Heart, Testes, Eye, Colon, Lymph Node, T Cells, Bone

Publications for Chagas Disease

Articles related to Chagas Disease:

(show top 50) (show all 852)
# Title Authors Year
1
Anticoagulation in patients with cardiac manifestations of Chagas disease and cardioembolic ischemic stroke. ( 29364390 )
2018
2
Chagas disease and systemic autoimmune diseases among Bolivian patients in Switzerland. ( 29412344 )
2018
3
Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial. ( 29352704 )
2018
4
High prevalence of S. Stercoralis infection among patients with Chagas disease: A retrospective case-control study. ( 29385128 )
2018
5
Chagas Disease Recommendations for Solid-Organ Transplant Recipients and Donors. ( 29381572 )
2018
6
Looking for combination of benznidazole and Trypanosoma cruzi-triosephosphate isomerase inhibitors for Chagas disease treatment. ( 29412353 )
2018
7
cDNA Isolation and Expression of Nicotinamide Adenine Dinucleotide Phosphate-Dependent Cytochrome P450 Reductase Gene in the Chagas Disease Vector<i>Triatoma infestans</i>. ( 29363459 )
2018
8
"It's Like a Phantom Disease": Patient Perspectives on Access to Treatment for Chagas Disease in the United States. ( 29380723 )
2018
9
Inhibitors of Trypanosoma cruzi Sir2 related protein 1 as potential drugs against Chagas disease. ( 29357372 )
2018
10
Prevalence of Chagas Disease among Solid Organ-Transplanted Patients in a Nonendemic Country. ( 29405102 )
2018
11
Quantitative and histological assessment of maternal-fetal transmission of Trypanosoma cruzi in guinea pigs: An experimental model of congenital Chagas disease. ( 29364882 )
2018
12
The long road towards a safe and effective treatment of chronic Chagas disease. ( 29352705 )
2018
13
What to expect and when: benznidazole toxicity in chronic Chagas' disease treatment. ( 29351667 )
2018
14
Nucleotide and nucleoside involvement in immunomodulation in experimental Chagas disease. ( 29404886 )
2018
15
Technological innovation strategies for the specific treatment of Chagas disease based on Benznidazole. ( 29452113 )
2018
16
Usefulness of FC-TRIPLEX Chagas/Leish IgG1 as confirmatory assay for non-negative results in blood bank screening of Chagas disease. ( 29395166 )
2018
17
Treatment with low doses of aspirin during chronic phase of experimental Chagas' disease increases oesophageal nitrergic neuronal subpopulation in mice. ( 29349896 )
2018
18
Molecular characterization of Rhodnius robustus specimens, potential vectors for Chagas disease in French Guiana, South America. ( 29378264 )
2018
19
Leishmanicidal and Trypanocidal Activity of Metal Complexes with 1,2,4-Triazolo[1,5-a]pyrimidines: Insights on their Therapeutic Potential against Leishmaniasis and Chagas Disease. ( 28521698 )
2017
20
Chagas disease research and development: Is there light at the end of the tunnel? ( 28066534 )
2017
21
Combined parasitological and molecular-based diagnostic tools improve the detection of Trypanosoma cruzi in single peripheral blood samples from patients with Chagas disease. ( 28954072 )
2017
22
Rapid diagnostic tests duo as alternative to conventional serological assays for conclusive Chagas disease diagnosis. ( 28369081 )
2017
23
The continuous challenge of Chagas disease treatment: bridging evidence-based guidelines, access to healthcare, and human rights. ( 29340449 )
2017
24
Morphology of the spermathecae of twelve species of Triatominae (Hemiptera, Reduviidae) vectors of Chagas disease. ( 28859957 )
2017
25
Cardiac inflammation and ventricular tachycardia in Chagas disease. ( 28840107 )
2017
26
Regarding Perspective Piece from July 2016 "What Do We Know About Chagas Disease in the United States?" ( 28471741 )
2017
27
Ecological and physiological thermal niches to understand distribution of Chagas disease vectors inA Latin America. ( 28857300 )
2017
28
Chagas disease: national survey of seroprevalence in children under five years of age conducted in 2008. ( 28443980 )
2017
29
Autochthonous Chagas disease in the southern United States: A case report of suspected residential and military exposures. ( 28418113 )
2017
30
Understanding transmissibility patterns of Chagas disease through complex vector-host networks. ( 28077180 )
2017
31
Molecular and serological detection of Trypanosoma cruzi in dogs (Canis lupus familiaris) suggests potential transmission risk in areas of recent acute Chagas disease outbreaks in Colombia. ( 28532988 )
2017
32
Chagas Disease (American Trypanosomiasis) ( 29083573 )
2017
33
Etiological Classification of Stroke in Patients with Chagas Disease Using TOAST, Causative Classification System TOAST, and ASCOD Phenotyping. ( 28844546 )
2017
34
Chagas disease and liver transplantation: Experience in Argentina using real-time quantitative PCR for early detection and treatment. ( 28941300 )
2017
35
Correction: Methodological approach to the ex vivo expansion and detection of T. cruzi-specific T cells from chronic Chagas disease patients. ( 28859177 )
2017
36
Strongyloides stercoralis infection increases the likelihood to detect Trypanosoma cruzi DNA in peripheral blood in Chagas disease patients. ( 28869694 )
2017
37
Prevalence of Chagas Disease in a U.S. Population of Latin American Immigrants with Conduction Abnormalities on Electrocardiogram. ( 28056014 )
2017
38
Unraveling Chagas disease transmission through the oral route: Gateways to Trypanosoma cruzi infection and target tissues. ( 28379959 )
2017
39
Angiotensin-Converting Enzyme ID Polymorphism in Patients with Heart Failure Secondary to Chagas Disease. ( 28977050 )
2017
40
Access to benznidazole for Chagas disease in the United States-Cautious optimism? ( 28910299 )
2017
41
Chagas disease in Europe: A long way to go. ( 28951077 )
2017
42
Chagas disease in Europe: A review for the internist in the globalized world. ( 28502864 )
2017
43
Modeling Chagas disease in Chile: From vector to congenital transmission. ( 28435013 )
2017
44
Benznidazole approved for Chagas disease in children. ( 28947517 )
2017
45
The Prevalence of Trypanosoma cruzi, the Causal Agent of Chagas Disease, in Texas Rodent Populations. ( 28091763 )
2017
46
Lack of association between serum syndecan-4, myocardial fibrosis and ventricular dysfunction in subjects with chronic Chagas disease. ( 29232393 )
2017
47
The process of lipid storage in insect oocytes: The involvement of I^-chain of ATP synthase in lipophorin-mediated lipid transfer in the chagas' disease vector Panstrongylus megistus (Hemiptera: Reduviidae). ( 27983943 )
2017
48
Development of Diagnostics for Chagas Disease: Where Should We Put Our Limited Resources? ( 28056025 )
2017
49
Cell therapies for Chagas disease. ( 28887011 )
2017
50
Participation of TLR2 and TLR4 in Cytokines Production by Patients with Symptomatic and Asymptomatic Chronic Chagas Disease. ( 27783847 )
2017

Variations for Chagas Disease

Expression for Chagas Disease

Search GEO for disease gene expression data for Chagas Disease.

Pathways for Chagas Disease

Pathways related to Chagas Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 95)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.2 CALR CCL2 CCL3 CCR5 CXCL8 IFNG
2
Show member pathways
13.97 CCL2 CCL3 CCR5 CXCL8 IL10 IL12B
3
Show member pathways
13.85 CCL2 CCL3 CCR5 CXCL8 IFNG IL10
4
Show member pathways
13.7 CCL2 CCL3 CXCL8 IFNG IL10 IL12B
5
Show member pathways
13.62 CCL2 CCL3 CCR5 CXCL8 IL10 IL12B
6
Show member pathways
13.56 CCL2 CCL3 CCR5 CXCL8 IFNG IL10
7
Show member pathways
13.5 CCL2 CCL3 CCR5 CXCL8 IL10 IL12B
8
Show member pathways
13.15 CCL2 CXCL8 IL1B IL6 NOS2 TLR2
9
Show member pathways
13.09 CALR CXCL8 IFNG IL10 IL12B IL1B
10
Show member pathways
13.03 CCL2 CXCL8 IFNG IL12B IL1B IL2
11 13 CXCL8 IFNG IL12B IL2 IL6 NOS2
12
Show member pathways
12.88 IL1B IL2 IL6 TGFB1 TLR2 TLR4
13
Show member pathways
12.86 CXCL8 IFNG IL12B IL1B IL6 TNF
14
Show member pathways
12.85 ACE CALR CCL2 CCL3 CXCL8 IFNG
15
Show member pathways
12.84 CCL2 IFNG IL10 IL12B IL1B IL2
16
Show member pathways
12.8 IFNG IL10 IL12B IL1B IL2 IL6
17
Show member pathways
12.77 CCR5 CXCL8 IL6 TGFB1 TLR2 TLR4
18 12.77 CCL2 IFNG IL10 IL1B IL2 TLR2
19
Show member pathways
12.73 IFNG IL10 IL12B IL2 TNF
20
Show member pathways
12.7 IL12B IL1B TLR2 TLR4 TNF
21
Show member pathways
12.68 CCR5 IFNG IL10 IL1B IL2 IL6
22
Show member pathways
12.57 CCL2 CXCL8 IFNG IL1B IL6 TLR2
23 12.56 CALR IL2 IL6 TGFB1 TNF
24
Show member pathways
12.53 CCL2 IFNG IL1B IL2 IL6 TNF
25
Show member pathways
12.52 IFNG IL10 IL12B IL2 IL6
26
Show member pathways
12.52 CXCL8 IFNG IL1B IL6 NOS2 TLR4
27
Show member pathways
12.47 CCR5 IFNG IL10 IL12B IL1B NOS2
28 12.45 IL12B TGFB1 TLR2 TLR4 TNF
29 12.44 IFNG IL6 NOS2 TGFB1 TLR2 TLR4
30
Show member pathways
12.44 CXCL8 IFNG IL1B IL6 NOS2 TLR2
31 12.43 IFNG IL10 IL12B IL1B IL6 NOS2
32
Show member pathways
12.42 CXCL8 IL6 TLR2 TLR4 TNF
33
Show member pathways
12.4 CXCL8 IFNG IL10 IL12B IL1B IL2
34 12.35 CXCL8 IL10 IL1B IL6 TNF
35
Show member pathways
12.31 IFNG IL1B TLR4 TNF
36
Show member pathways
12.31 ACE IL6 TGFB1 TNF
37
Show member pathways
12.25 CCL3 CCR5 IFNG IL12B IL1B IL2
38 12.22 CCL2 CXCL8 IL10 IL12B IL1B IL6
39 12.21 CCL2 IFNG IL1B TNF
40 12.19 IFNG IL10 IL2 IL6 TNF
41 12.19 CCL3 CXCL8 IFNG IL1B IL6 TGFB1
42 12.17 IFNG IL1B TGFB1 TNF
43
Show member pathways
12.16 IL1B IL2 TLR2 TLR4
44 12.16 CCL2 CXCL8 IL1B IL6 TGFB1 TNF
45 12.16 CXCL8 IFNG IL10 IL12B IL1B IL6
46
Show member pathways
12.13 IFNG IL12B IL1B IL6 TGFB1 TLR2
47
Show member pathways
12.12 CCL2 CCL3 CCR5 CXCL8
48
Show member pathways
12.12 IFNG IL10 IL12B IL1B IL2 IL6
49 12.1 CCL3 CXCL8 IFNG IL1B IL6 NOS2
50 12.09 CCL2 IL1B IL6 TNF

GO Terms for Chagas Disease

Cellular components related to Chagas Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intracellular GO:0005622 9.81 CALR CCL2 CCL3 CXCL8 IFNG IL2
2 cell surface GO:0009986 9.8 CALR CCR5 TGFB1 TLR2 TLR4 TNF
3 extracellular region GO:0005576 9.8 ACE CALR CCL2 CCL3 CXCL8 IFNG
4 external side of plasma membrane GO:0009897 9.65 ACE CALR CCR5 TLR4 TNF
5 extracellular space GO:0005615 9.47 ACE CALR CCL2 CCL3 CXCL8 IFNG

Biological processes related to Chagas Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 97)
# Name GO ID Score Top Affiliating Genes
1 cellular response to interferon-gamma GO:0071346 9.99 CCL2 CCL3 IL12B NOS2
2 defense response to Gram-negative bacterium GO:0050829 9.99 IL12B IL6 NOS2 TLR4
3 response to organic substance GO:0010033 9.99 CALR IL10 IL12B TGFB1 TNF
4 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.99 IL1B IL6 TGFB1 TLR2 TLR4 TNF
5 chemokine-mediated signaling pathway GO:0070098 9.98 CCL2 CCL3 CCR5 CXCL8
6 regulation of insulin secretion GO:0050796 9.97 IFNG IL1B NOS2 TNF
7 cellular response to organic cyclic compound GO:0071407 9.97 CCL2 CCL3 IL1B TGFB1 TNF
8 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.96 IFNG IL12B IL2 IL6
9 positive regulation of inflammatory response GO:0050729 9.96 CCL3 IL12B IL2 TLR2 TLR4
10 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.95 IL6 TGFB1 TNF
11 cellular response to mechanical stimulus GO:0071260 9.95 IL1B TGFB1 TLR4
12 neutrophil chemotaxis GO:0030593 9.95 CCL2 CCL3 CXCL8 IL1B
13 cellular response to interleukin-1 GO:0071347 9.94 CCL2 CCL3 CXCL8
14 positive regulation of JNK cascade GO:0046330 9.94 IL1B TLR4 TNF
15 response to glucocorticoid GO:0051384 9.94 IL10 IL6 TNF
16 positive regulation of T cell proliferation GO:0042102 9.94 IL12B IL1B IL2 IL6
17 interleukin-12-mediated signaling pathway GO:0035722 9.92 IFNG IL10 IL12B
18 calcium-mediated signaling GO:0019722 9.92 CCL3 CCR5 CXCL8
19 negative regulation of fat cell differentiation GO:0045599 9.92 IL6 TGFB1 TNF
20 humoral immune response GO:0006959 9.92 CCL2 IFNG IL6 TNF
21 monocyte chemotaxis GO:0002548 9.91 CCL2 CCL3 IL6
22 extrinsic apoptotic signaling pathway GO:0097191 9.91 IFNG TGFB1 TNF
23 positive regulation of tumor necrosis factor production GO:0032760 9.91 CCL3 IL12B TLR2 TLR4
24 response to bacterium GO:0009617 9.9 CCL2 NOS2 TLR4
25 negative regulation of mitotic cell cycle GO:0045930 9.9 IL10 TGFB1 TNF
26 positive regulation of nitric oxide biosynthetic process GO:0045429 9.9 IFNG IL1B TLR4 TNF
27 positive regulation of phagocytosis GO:0050766 9.89 CALR IL1B TNF
28 protein import into nucleus, translocation GO:0000060 9.89 IFNG TGFB1 TNF
29 negative regulation of interleukin-6 production GO:0032715 9.89 IL10 TLR4 TNF
30 positive regulation of interleukin-6 production GO:0032755 9.89 IL1B IL6 TLR2 TLR4 TNF
31 positive regulation of protein complex assembly GO:0031334 9.88 IFNG TGFB1 TNF
32 positive regulation of interleukin-8 production GO:0032757 9.88 IL1B TLR2 TLR4 TNF
33 positive regulation of interleukin-12 production GO:0032735 9.88 IFNG IL12B TLR2 TLR4
34 protein kinase B signaling GO:0043491 9.88 CCL2 CCL3 IL1B TGFB1 TNF
35 positive regulation of interleukin-10 production GO:0032733 9.87 IL12B TLR2 TLR4
36 positive regulation of osteoclast differentiation GO:0045672 9.86 IFNG IL12B TNF
37 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.85 IFNG IL1B TNF
38 cell activation GO:0001775 9.85 CCL3 TGFB1 TLR2
39 positive regulation of chemokine production GO:0032722 9.85 IL6 TLR2 TLR4 TNF
40 positive regulation of interferon-gamma production GO:0032729 9.85 IL12B IL1B IL2 TLR4 TNF
41 negative regulation of growth of symbiont in host GO:0044130 9.83 IL10 IL12B TNF
42 regulation of regulatory T cell differentiation GO:0045589 9.83 IFNG IL2 TGFB1
43 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.82 CCL2 TLR2 TLR4
44 positive regulation of interleukin-17 production GO:0032740 9.81 IL12B IL2 TGFB1
45 cellular response to lipopolysaccharide GO:0071222 9.81 CCL2 CCR5 CXCL8 IL10 IL12B IL6
46 response to molecule of bacterial origin GO:0002237 9.8 CXCL8 IL10 TLR2
47 positive regulation of NF-kappaB import into nucleus GO:0042346 9.8 IL12B IL1B TLR2 TLR4 TNF
48 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.79 IL10 IL1B TNF
49 response to cholesterol GO:0070723 9.79 CCL3 CCR5 TGFB1
50 T-helper 1 type immune response GO:0042088 9.77 IL12B TLR4

Molecular functions related to Chagas Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chemokine activity GO:0008009 9.43 CCL2 CCL3 CXCL8
2 cytokine activity GO:0005125 9.36 CCL2 CCL3 CXCL8 IFNG IL10 IL12B
3 growth factor activity GO:0008083 9.35 IL10 IL12B IL2 IL6 TGFB1
4 lipopolysaccharide receptor activity GO:0001875 9.16 TLR2 TLR4
5 protein binding GO:0005515 10.25 CALR CCL2 CCL3 CCR5 CXCL8 IFNG

Sources for Chagas Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....